Stephen is the founder and Chief Executive Officer of Vulpes Investment Management, and co-founder and former managing partner of Artradis Fund Management, one of the largest hedge fund groups in Asia.  Stephen has been involved in equity capital markets for nearly 30 years, leading trading teams across a number of institutions including Salomon Brothers and Lehman Brothers, and has considerable experience investing in and supporting life science businesses through the Vulpes Life Sciences Fund.  Stephen holds an MA from the University of Oxford.

Christian read Politics, Philosophy and Economics at Lincoln College, Oxford.  His career started at the Boston Consulting Group where he worked both in Europe and the US. He then moved to the UK Holding Company a subsidiary of the German/Dutch Conglomerate, Hoogovens/Hoechst as a director of two of their subsidiaries in the UK, winning the Queen’s award for Exports in one of those subsidiaries. He then became Vice President of Fox Pitt Kelton, where he worked on the mergers and acquisitions of US Regional Banks.  Subsequently, Christian embarked on career in venture capital, initially in conjunction with Ensign Trust PLC, owned by the Merchant Navy Pension Fund.  Christian founded Oxford BioDynamics in 2007 with Dr. Alexandre Akoulitchev and Dr. Aroul Ramadass.  Christian was the Chairman of both Chronos Therapeutics Limited and Sibelius Limited until August 2016, at which point he stepped down from both roles.   He is now a Non-Executive Director of both Chronos Therapeutics Limited and Sibelius Limited. Christian sits on the Nomination Committee.

Alexandre Akoulitchev

Alexandre read mathematics, physics, chemistry, biochemistry and biophysics at Moscow Institute of Physics and Technology.  In 1989 he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students from the USSR. He obtained his PhD in cell biology from University College, London (with the research based at the Imperial Cancer Research Fund). He spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford.  He was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College, sponsored by Cancer Research UK, the Wellcome Trust, The Medical Research Council and Monsanto Foundation.  Alexandre is also a Fellow of the Royal Society of Medicine.  He is currently a Non-Executive Director of Sibelius Limited.

Paul joined the Company in September 2017 from e-Therapeutics plc, where he held the position of Financial Controller from 2012. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors.  He read Natural Sciences at St John’s College, University of Cambridge.

Dr David Holbrook is a proven leader in business development and healthcare investing, with 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.

Dr. Peter Pack, currently Chief Executive Officer of Crescendo Biologics, brings over 25 years’ experience of successfully establishing and growing international life sciences companies. At Crescendo, he has led the company through a $70 million fund raising and successfully completed a major licensing deal with Takeda for up to $790 million in milestones, with $36 million in upfront fees, equity investment and near-term milestones. Peter will shortly step down as CEO at Crescendo, continuing to serve the company as a senior advisor. Previously, Peter has served on a number of Boards and has headed up companies with up to 400 employees in the role of CEO and Managing Director, including mtm laboratories AG, where as co-founder and CEO he was responsible for the development, production and commercialisation of in vitro diagnostics for population-wide screening of cervical cancer. Peter is also a Board member of PolyPlus Transfections SA.